Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
J Cosmet Dermatol ; 21(10): 4107-4113, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-1949600


BACKGROUND: Delayed inflammatory reactions (DIRs) to hyaluronic acid-based dermal fillers following COVID-19 vaccination has been reported in a few anecdotal reports and small series of cases. AIM: To evaluate the clinical characteristics, incidence, and management options relevant to BNT162b2 vaccination-associated DIR-A nationwide survey was conducted. METHODS: An online self-administered survey was sent to physicians who actively practice tissue filler injections. The data acquired included demographic and clinical characteristics of relevant DIR cases. RESULTS: Out of 262 responders, 20 cases with DIR following the vaccination were reported. 35% and 65% occurred shortly after the first and second vaccination dose, respectively. Overall, 65% of the DIRs appeared ≤5 days after vaccine administration and most DIRs resolved within 21 days. The filler's volume (p = 0.016) was associated with higher DIR severity, and the same tendency was noted among some filler types and locations of injection. Medical intervention was provided in 12 (60%) cases. CONCLUSION: DIR associated with BNT162b2 vaccination is rare and tends to resolve spontaneously or with short-term medical intervention.

BNT162 Vaccine , COVID-19 , Dermal Fillers , Hyaluronic Acid , Inflammation , Humans , BNT162 Vaccine/adverse effects , Cosmetic Techniques/adverse effects , COVID-19/prevention & control , Dermal Fillers/adverse effects , Hyaluronic Acid/adverse effects , Vaccination/adverse effects , Inflammation/chemically induced , Inflammation/epidemiology
6th International Conference on Trends in Electronics and Informatics, ICOEI 2022 ; : 554-559, 2022.
Article in English | Scopus | ID: covidwho-1901454
Chinese Journal of Applied Clinical Pediatrics ; 36(24):1913-1917, 2021.
Article in Chinese | Scopus | ID: covidwho-1765983
Journal of Cosmetic Dermatology ; n/a(n/a), 2022.
Article in English | Wiley | ID: covidwho-1714236
Front Pharmacol ; 12: 650425, 2021.
Article in English | MEDLINE | ID: covidwho-1268274


Inflammasomes are large multimolecular complexes best recognized because of their ability to control activation of caspase-1, which in turn regulates the maturation of interleukin-18 (IL-18) and interleukin-1 ß (IL-1ß). IL-1ß was originally identified as a pro-inflammatory cytokine, capable of inducing local and systemic inflammation as well as a fever response reaction in response to infection or injury. Excessive production of IL-1ß is related to inflammatory and autoimmune diseases. Both coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) are characterized by excessive inflammatory response. For SARS, there is no correlation between viral load and worsening symptoms. However, there is no specific medicine which is available to treat the disease. As an important part of medical practice, TCM showed an obvious therapeutic effect in SARS-CoV-infected patients. In this article, we summarize the current applications of TCM in the treatment of COVID-19 patients. Herein, we also offer an insight into the underlying mechanisms of the therapeutic effects of TCM, as well as introduce new naturally occurring compounds with anti-coronavirus activity, in order to provide a new and potential drug development strategy for the treatment of COVID-19.

Stem Cells Transl Med ; 10(6): 883-894, 2021 06.
Article in English | MEDLINE | ID: covidwho-1060671


While mesenchymal stromal cells are an appealing therapeutic option for a range of clinical applications, their potential to induce clotting when used systemically remains a safety concern, particularly in hypercoagulable conditions, such as in patients with severe COVID-19, trauma, or cancers. Here, we tested a novel preclinical approach aimed at improving the safety of mesenchymal stromal cell (MSC) systemic administration by use of a bioreactor. In this system, MSCs are seeded on the exterior of a hollow-fiber filter, sequestering them behind a hemocompatible semipermeable membrane with defined pore-size and permeability to allow for a molecularly defined cross talk between the therapeutic cells and the whole blood environment, including blood cells and signaling molecules. The potential for these bioreactor MSCs to induce clots in coagulable plasma was compared against directly injected "free" MSCs, a model of systemic administration. Our results showed that restricting MSCs exposure to plasma via a bioreactor extends the time necessary for clot formation to occur when compared with "free" MSCs. Measurement of cell surface data indicates the presence of known clot inducing factors, namely tissue factor and phosphatidylserine. Results also showed that recovering cells and flushing the bioreactor prior to use further prolonged clot formation time. Furthermore, application of this technology in two in vivo models did not require additional heparin in fully anticoagulated experimental animals to maintain target activated clotting time levels relative to heparin anticoagulated controls. Taken together the clinical use of bioreactor housed MSCs could offer a novel method to control systemic MSC exposure and prolong clot formation time.

Bioreactors , COVID-19/therapy , Cell Culture Techniques/methods , Mesenchymal Stem Cell Transplantation/methods , Thrombosis/prevention & control , Animals , Anticoagulants/pharmacology , Blood Coagulation Tests , Bone Marrow Cells/cytology , Cells, Cultured , Dogs , Heparin/pharmacology , Humans , Male , Membranes, Artificial , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/metabolism , Myocardial Infarction/pathology , Myocardial Infarction/prevention & control , SARS-CoV-2 , Swine